1973results about "Liposomal delivery" patented technology

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

The invention provides an enzyme response type supramolecular PDRN-mini ECM liposome and a preparation method and application thereof.The enzyme response type supramolecular PDRN-mini ECM liposome comprises phospholipid, a membrane stabilizer, a supramolecular compound and an emulsifier, a water phase formed by the supramolecular compound and the emulsifier serves as an inner core, and the supramolecular compound is formed by PDRN and mini ECM through intermolecular acting force; the mini ECM is formed by self-assembly of collagen peptide, elastin and hyaluronic acid. The supramolecular PDRN-mini ECM liposome with uniform particle size and good stability is obtained through a microfluidic technology, the process is simple, the controllability is high, and amplification is easy.

The invention discloses a macrophage-targeting inhalable nano material, a preparation method thereof and application of the inhalable nano material in treatment of sepsis myocarditis, and belongs to the technical field of medicines. The nano-material is a nano-liposome, the nano-liposome comprises a mannose modified nano-liposome microsphere, and the mannose modified nano-liposome microsphere comprises a liposome skeleton shell layer, a drug and a targeting layer; the liposome skeleton shell layer comprises soybean lecithin and cholesterol; the medicine comprises quercetin and TPPU (Thermoplastic Polyurethane); and the targeting layer is formed by connecting mannose modified DSPE-PEG2000 to the outer surface of the liposome skeleton shell layer. The nano material can accurately target macrophages at a cardiac inflammation part, has a multi-target-point synergistic effect, is more convenient and faster in administration, remarkably improves the safety and comprehensively improves the treatment effect.

The present invention provides, among other things, improved pharmaceutical compositions comprising codon-optimized mRNA encoding a peptide or polypeptide encapsulated in a lipid nanoparticle comprising one or more of the cationic lipids that are particularly effective for pulmonary delivery.

Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The application relates to the technical field of traditional Chinese medicines, in particular to a uric acid reducing composition and a preparation method thereof. The uric acid reducing composition comprises 35-45 parts of a cyclodextrin inclusion compound, 25-35 parts of nano-liposomes, 20-30 parts of a chicory extract-phospholipid complex and 5-8 parts of an antioxidant complex; the preparation method of the cyclodextrin inclusion compound comprises the following steps: step 1, adding beta-cyclodextrin into water, stirring and dissolving, adding pueraria extract, drying after inclusion reaction, and obtaining inclusion compound a; step 2, adding hydroxypropyl-gamma-cyclodextrin into water, stirring, adding mulberry leaf extract, drying after inclusion, and obtaining inclusion compound b; and step 3, mixing the inclusion compound a and the inclusion compound b, and obtaining the product. The uric acid reducing composition can more comprehensively and efficiently reduce blood uric acid level, and has high safety, high stability and high bioavailability. The preparation method is simple, easy to industrialize and beneficial to large-scale industrial production.

The present invention provides a method for producing nucleic acid-encapsulating lipid nanoparticles, including the following steps (a) and (b): step (a) of mixing an alcohol solution containing an ionic lipid having a tertiary amino group, a sterol, and a PEG lipid with a citrate buffer having pH 3 to 6.5 in which nucleic acid is dispersed to prepare a suspension of nucleic acid-encapsulating lipid nanoparticles; and step (b) of exchanging a dispersion medium of the aforementioned suspension for a Tris buffer having pH 5.2 to 9.0 by concentrating the suspension of nucleic acid-encapsulating lipid nanoparticles by ultrafiltration and diluting same with the aforementioned Tris buffer.

Disclosed are compositions and methods useful for targeting and internalizing molecules into cells of interest and for penetration by molecules of tissues of interest. The compositions and methods are based on peptide sequences that are selectively internalized by a cell, penetrate tissue, or both. The disclosed internalization and tissue penetration is useful for delivering therapeutic and detectable agents to cells and tissues of interest.

The present invention relates to a 3D printing composite hydrogel microneedle, the 3D printing composite hydrogel microneedle comprises methacrylated chitosan, o-nitrobenzyl alcohol polyethylene glycol, resveratrol and a liposome, and the resveratrol is entrapped in the liposome. The preparation method comprises the following steps: preparing resveratrol-loaded lipidosome, and preparing the 3D printing composite hydrogel microneedle. Through organic combination of the pharmacological activity of resveratrol, the controllable skeleton of PEGNB, the adhesion and antibacterial characteristics of CSMA, the precise drug delivery capability of a microneedle and the precise preparation advantage of 3D printing, the innovative microneedle patch with long-acting drug delivery, excellent biocompatibility and myocardial repair function is provided; and a new solution is provided for myocardial injury treatment.

Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, primarily due to the lack of actionable immune targets. Novel tumor-specific antigens (TSAs) shared by the majority of AML cells are described herein. Most of the TSAs described herein are derived from aberrantly expressed, non-mutated genomic sequences that are not expressed in normal tissues, such as intronic and intergenic sequences. Nucleic acids, compositions, cells, and vaccines derived from these TSAs are described. Use of the TSAs, nucleic acids, compositions, cells, and vaccines for the treatment of leukemias, such as AML, is also described.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

Lipid nanoparticle compositions for the delivery of nucleic acids are provided.SOLUTION: In various embodiments, the lipid nanoparticle comprises an ionizable lipid of Formula (I). Also provided are methods of using such lipid nanoparticle compositions to achieve targeted delivery of therapeutic cargo without the need for a targeting ligand.SELECTED DRAWING: None

Disclosed herein are compositions and methods of use thereof for the prevention of mastitis in dairy cattle. The compositions and methods can have immunostimulant effectiveness against mastitis-causing bacteria. In particular embodiments, the methods include preventing mastitis infection by intramammary infusion of a disclosed composition at dry-off.

The invention belongs to the technical field of pharmaceutical preparations. The invention discloses a multifunctional bionic nano preparation, a preparation method and application. According to the multifunctional bionic nano preparation, the ginsenoside Rg3 has the dual functions of a medicine and a membrane stabilizer, the platelet membrane has the natural targeting capability on circulating tumor cells and metastases, and meanwhile, the cationic liposome is used for adsorbing negatively-charged NETs nucleic acid protein compounds, so that potential reversal and active targeting are achieved, and the multifunctional bionic nano preparation has a good application prospect. And by co-carrying paclitaxel (PTX) and a photothermal agent (PCP) and integrating photothermal-chemotherapy-immunogenic death (ICD) induction functions, the tumor-related fibroblast activation can be effectively inhibited, circulating tumor cells can be efficiently captured, a tumor immune microenvironment can be remodeled, the tumor cells can be effectively killed, and tumor distal metastasis can be inhibited.

The invention discloses a mannose modified liposome gel microsphere oral delivery system based on cations and application of the mannose modified liposome gel microsphere oral delivery system. The oral delivery system comprises a core layer and a wrapping layer, the core layer is mannose modified cationic liposome loaded with a mucous membrane adjuvant retinoic acid and an antigen, and the wrapping layer is sodium alginate gel vulcanized and modified by cysteine. The mannose modified cationic liposome is prepared by coupling mannose on the surface of the cationic liposome, and the cysteine modified sodium alginate gel is used for protecting antigens in the core layer from being eroded by gastric juice, enhancing the adhesiveness of a delivery system in the intestinal tract and prolonging the retention time of the delivery system in the intestinal tract; in addition, the R-MLip can be expanded and released under the environment that the pH of the intestinal tract is increased. The inside of the gel microsphere of the oral delivery system shows a regular net-shaped structure and has abundant holes and channels, and the oral delivery system shows a good prospect in the aspect of enhancing mucous membrane and systemic immunity and possibly becomes a potential substitute of a traditional attenuated live vaccine in the future.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

Methods and systems for analyzing lipid nanoparticles using size exclusion chromatograph coupled with multi angle light scattering are disclosed.

Compositions comprising an isolated population of nanovesicles from a plant, mushroom or algae are provided. Methods of treating muscle and bone diseases, treating neurological diseases, treating age-related disease, inducing muscle differentiation, inducing neuronal differentiation, treating malnutrition, reducing inflammation and reducing oxidative stress by administering a composition comprising an isolated population of nanovesicles from a plant, mushroom or algae are also provided. Methods of delivering a compound to a cell comprising loading the compound into nanovesicles from a plant, mushroom or algae and contacting the cell with the loaded nanovesicles are also provided.

The invention discloses a functional lipid compound for nano-liposome wrapping and a preparation method, and relates to the technical field of functional lipid compounds, the functional lipid compound comprises (a) a polyphenol-lipid covalent conjugate which is composed of a polyphenol active unit selected from curcumin, dihydroquercetin or derivatives thereof, and (b) a lipid covalent conjugate which is composed of a polyphenols active unit selected from curcumin, dihydroquercetin or derivatives thereof and a polyphenols active unit selected from curcumin, dihydroquercetin or derivatives thereof; the conjugate is covalently linked to a phosphatidyl ethanolamine or cholesterol skeleton through a cleavable linking group, and the conjugate can be integrated into a nano-liposome membrane and has the functions of structural support and biological activity; (b) a microenvironment-responsive functional phospholipid, which is a phospholipid derivative having a functional group responsive to an inflammatory microenvironment specific stimulus modified on a hydrophilic head group or a hydrophobic chain of a phospholipid molecule, the specific stimulus being selected from local pH < = 6.5, reactive oxygen species (ROS) concentration > = 10 [mu] M or matrix metalloproteinase MMP-2 / 9 overexpression; and (c) a bionic exosome membrane lipid component, wherein the bionic exosome membrane lipid component comprises sphingosine-based glycolipid or sulfated cholesterol separated from the plant-derived exosome.

(1) The purpose of the present invention is to provide an antitumor agent in which an effect of an immune checkpoint inhibitor is enhanced. (2) The purpose of the present invention is also to provide a drug that could exhibit an effect even under conditions in which no antigen is present. (1) Provided is an antitumor agent obtained by combining an immune checkpoint inhibitor with an NKT cell ligand-containing liposome composition. (2) Also provided is a liposome composition containing an NKT cell ligand and an antigen.

A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.

The present invention relates to RNA-containing vaccine compositions for inducing an immune response to Porphyromonas gulae in a subject, and uses thereof.

The present application relates to a kind of robecoxib liposome and its preparation method and application, the preparation raw material of the robecoxib liposome includes phospholipid, cholesterol and robecoxib, and the robecoxib is encapsulated in lipid bilayer, and the robecoxib liposome of the present application improves the solubility of robecoxib, and has higher encapsulation efficiency and drug loading.